Correct me if I am wrong, but Celgene's initial right of first refusal (RoFR) began on 13th April 2015, and their extension was until 13th October 2015.
They announced on the 16th October 2015 that they have extended Celgene's RoFR for another 6 months i.e. 16th April 2016.
So they made the announcement after the deadline ... which means they will probably do the same this time around if they were to further extend the RoFR.
If however they choose to execute a licensing deal, I would personally expect a trading halt.
And if Celgene decided to pass on their RoFR, then they know something we don't. Because there has been nothing but positive results coming out of the trials, and the effectiveness of MSB's treatments on other ailments just improves the robustness of MSB's approach. So going along the same vein as other posters, this is not a logical outcome. Celgene's commitment to buy 15.3 million shares supports the fact that they want to be vested in MSB's success in the long term.
Celgene Agreement, page-7
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.569B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12214 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 37660 | 5 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |